Expedition Therapeutics raises $115M Series B for China-sourced COPD candidate
read at Endpoints ↗DealPositive
Expedition Therapeutics, a US biotech, announced a $115 million Series B financing round.
The capital will be used to advance its COPD drug candidate that is being developed from a China-sourced program, reflecting a twist on the emerging NewCo partnership model.
The investment highlights strong investor confidence in the company's approach and could speed the candidate toward further clinical development.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Expedition gets another $115M for its twist on China NewCo model”
read at Endpoints ↗87 words · retrieved Aug 5
comments(0)
5-min edit window · permanent after that